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Abstract: Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an important therapeutic
advancement for the treatment of Parkinson’s disease (PD). Its beneficial effects on motor functions are
well established, but its cognitive, affective, and behavioral sequelae come increasingly into the focus
of the medical and ethical discussion. In order to evaluate whether these side effects may counteract
the beneficial effects of STN DBS on the patient’s quality of life, we classify them along the dimensions
“measurement complexity” and “weighted life-impact.” Based on this analysis, we discuss their ethical
impact and propose guidelines for the clinical setting of STN DBS.
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Dealing with Side Effects of Deep Brain Stimulation:  





Deep brain stimulation (DBS) is increasingly investigated as a therapy for psychiatric 
disorders. In the ethical evaluation of this novel approach, incidence and impact of side 
effects (SE) play a key role. In our contribution, we analyze the discussion on SE of DBS of 
the subthalamic nucleus (STN) – a standard therapy for movement disorders like Parkinson’s 
disease (PD) – based on 66 case reports, 69 review papers, and 347 outcome studies from 
1993 to 2009. We show how the DBS community increasingly acknowledged the complexity 
of STN-DBS side effects. Then we discuss the issue of study quality and the methods used to 
assess SE. We note that some side effects are subject of conflicting evaluations by the 
different stakeholders involved. This complicates the ethical controversy inherent in any 
novel treatments for diseases that involve psychiatric aspects. We delineate how the lessons 
from STN-DBS could guide future DBS applications in the field of psychiatry. 
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Since the advent of medicine, the maxim “do not harm your patient” forms the core of the 
ethos for physicians. This is reflected in the principle of nonmaleficience as one of the four 
principles of biomedical ethics (Beauchamp & Childress 2009). Nevertheless, it is broadly 
acknowledged that harmful side effects (SE) of therapies have to be weighed up against their 
beneficial effects. The deliberation of harms and ben fits becomes more difficult if side 
effects of novel therapeutic approaches have to be considered, of which nature, extent, and 
incidence are not yet known.  
 
Deep brain stimulation (DBS) is an example for a novel therapeutic approach. Its roots go 
back to the early 1950s (Hariz et al. 2010), and it emerged in its current form in the 1980s as 
an alternative for ablative surgery in movement disorders and an experimental therapy in 
chronic pain (Siegfried & Blons 1997). DBS became an established therapy for Parkinson’s 
disease (PD) and other movement disorders in the last decade (Benabid et al. 2009). Side 
effects have been discussed since the advent of DBS, but the sensibility for them and the 
appreciation of their complexity is increasing. This also reflects the maturation of the therapy. 
 
The term ‘side effect’ does not provide per se an ethical orientation how to deal with a 
specific therapy. Therefore terms like ‘adverse events’ or ‘sequelae’ (adverse events that 
count as long-term negative consequences) should be avoided as long as the negative 
evaluation of the side effect is not clear. For evaluating particular side effects, they can be 
classified along the two dimensions predictability and evaluation (Table 1).  
 
INSERT TABLE 1 
 
Table 1:  Ethical requirements depending on the predictability and the evaluation of the side effects of a 
therapy.  
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As Table 1 shows, only one type of side effects (predictable and clearly outweighing the 
benefits) bears the clear “ethical message” that the therapy should not be applied or that 
research on this therapy should be stopped. Thus, the determination of what counts as an 
adverse event involves both a measurement problem and an evaluation problem which can be 
entangled in the process of developing the therapy (Müller & Christen 2011). DBS for PD 
patients is a paradigmatic example for outlining that problem, since first the predictability of 
side effects for individual patients is difficult, second the evaluation of some side effects 
differs significantly between patients, their relatives and physicians (Müller & Christen 2011), 
and third both the disease (Kulisevsky et al. 2008) and alternative therapeutic approaches 
(medication or surgery, see Voon et al. 2006 and Olanow 2002) may involve similar effects as 
DBS. 
 
The following investigation is based on a comprehensive literature analysis of the research 
literature on DBS in the nucleus subthalamicus (STN), the preferred target for DBS in PD. 
This analysis covers 66 case reports, 69 review papers, and 347 outcome studies from 1993 to 
2009 that emerged from an extensive search in the following databases: CPCI-S, Embase, 
Francis, Medline, PsychINFO and SCI-expanded (the reference lists are available as 
supporting online material).  
 
As the STN is part of various thalamo-cortical circuits (Marani et al 2008), the relatively high 
incidence of cognitive and affective side effects after STN DBS compared to other DBS 
targets is not surprising (Hariz et al. 2008). The way the DBS community dealt with this issue 
is thus a paradigmatic case for analyzing SE measurement and evaluation in the course of the 
establishment of novel therapies. Understanding this process may support the ethical analysis 
of the current application of DBS to a variety of psychiatric disorders (for an overview about 
psychiatric DBS see Krack et al. 2010).  
 
 
The complexity of adverse events 
 
Since the early 1990s, the STN was investigated as a potential DBS target both in animal and 
clinical studies. In 1993, the first case was published in a French journal (Pollak et al. 1993). 
Several case reports and outcome studies followed, and since the late 1990s the number of 
publications on STN-DBS has increased steadily (Müller & Christen 2011). The number of 
STN-DBS related issues discussed in the literature has grown rapidly, whereas a bibliometric 
investigation demonstrated that case reports spearhead the transdisciplinary communication 
about DBS (Christen & Müller 2011).  
 
To handle the complexity of issues that are discussed in our literature body of 482 STN-DBS 
publications, we have sorted them into 18 issue classes (Table 2). For each class, we have 
evaluated all tests used in the outcome literature to measure the respective phenomena and the 
wording used to describe the corresponding SE. Note that not each issue class is directly 
related to SE. This is true especially for studies on the neuronal basis of DBS effects (usually 
investigated by PET) or about the cost-effectiveness of DBS. Furthermore, the boundaries 
between some issue classes are less clear and required predefinitions. For example, we have 
classified studies about language fluency as ‘cognitive’ (in accordance with the current 
neuropsychological understanding). 
 
Each publication (case report, review, outcome study) was attributed to one or several issue 
classes with regard to the topics discussed and the methods used. Thereby we did not take into 
account possible causal relations between certain issues. For example, many issues have an 
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impact on the quality of life (Q). Nevertheless, a study whose, e.g., primary focus was 
insomnia was only classified as ‘I’, not as ‘Q’. For analyzing the time course of the 
publication praxis, it was necessary to build bigger groups. Therefore we have grouped the 18 
issue classes into four groups as follows: 
 
1. Group: Understanding therapeutic effects: F, M, V 
2. Group: Medical and technical intervention issues: O, P, T 
3. Group: Main affective, behavioral and cognitive side effects of DBS: B, C, D, L, Q 
4. Group: Other issues: A, E, I, K, N, S, W 
 
INSERT TABLE 2 
 
Table 2:  Issue classes of therapeutic effects and side effects present in the STN-DBS literature. Only 
selected examples of side effects using the wording found in the publications are displayed. 
 
The histogram in Fig. 1 shows the time-course of the different groups of issues in the DBS 
literature. The absolute numbers of publications per year belonging to one of the four issue 
groups are displayed for the years 1993 to 2009. The analysis reveals that – after the first, 
pioneering years with very few studies – issues on main affective, behavioral and cognitive 
side effects quickly appeared in the literature and became the dominant group since 2003. 
This finding is corroborated by an analysis of DBS posters presented at conferences (Christen 
& Müller 2011). Although one has to take into account that this analysis is not sensible for the 
valuation of these effects (i.e. whether they are considered to be unproblematic or not), this 
finding somehow contrasts with several statements in the literature, that the DBS community 
would often ignore the neurobehavioral consequences of the therapy (e.g., Burn & Tröster 
2004). 
 
INSERT FIGURE 1 
 
Figure 1:  The histogram displays the total number of issues (compare with Table 2) addressed in the 
publications about STN-DBS (case reports, reviews, and outcome studies) pooled in four 
groups (Group 1: F, M, V / Group 2: O, P, T / Group 3: B, C, D, L, Q / Group 4: A, E, I, K, N, 
S, W; see text).   
 
 
Quality of STN-DBS studies 
 
The sensibility for novel side effects in the process of maturation of a novel therapy is a 
critical issue – and we may say that the DBS community has passed this test successfully. 
Another issue is the quality of the studies. Although it is well-known that novel therapies start 
with isolated case studies that usually lack quality criteria like randomization or blinding, at 
some point the urge for better studies is raised. DBS did not deviate from this development 
path, and various authors have discussed the issue of study quality (e.g. Woods et al. 2006) 
and proposed standards for improving study quality (e.g. Morrison et al. 2000). We 
investigated the study quality for all outcome studies that involved at least one issue of group 
3 (i.e.: B, C, D, L, or Q). For that, we expanded the criteria for level of evidence assignment 
proposed by Martinez-Martin & Deuschl (2007) using a rating system that involves several 
aspects being considered as relevant for study quality (e.g. regarding follow-up time) by the 
DBS community.i 
 
As Fig. 2.a demonstrates, the quality range of the studies is broad. Somewhat surprising is the 
fact that the mean quality of the outcome studies did not increase significantly since 2000 
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(Fig. 2.b; earlier studies where not taken into account due to their low numbers). Although the 
absolute number of high quality studies of group 3 has increased, they are shrouded by the 
also increasing number of outcome studies of poor quality.  
 
This absent increase of the average study quality is not per se problematic, as long as the 
community is able to differ between good and poor studies. To investigate whether this is the 
case, we calculated a citation coefficient based on DBS review papers about the outcome 
studies of group 3.ii Then we performed a correlation analysis of the relationship of this 
citation coefficient and the quality rating for each study. The result is a (weak) positive 
correlation of the citation coefficient with the quality rating (Pearson's correlation coefficient: 
0.29). That means that high quality papers tend to be cited more often in the reviews. This can 
be interpreted as a hint for a higher appreciation of high quality studies of group 3 by the DBS 
community.  
 
INSERT FIGURE 2 
 
Figure 2:  (a) Quality rating distribution of the outcome studies of group 3, (b) time-course of the mean 
quality rating of outcome studies (group 3), (c) correlation between the citation coefficient of 
studies (which reflects the appreciation of papers by the authors of reviews) with the quality 
rating of the studies. The chart also includes the linear approximation of the correlation.  
 
 
Measuring Adverse Events 
 
After investigating the attention for side effects of group 3 and the quality of the studies 
investigating them, we investigated a third issue: To what extent do the studies capture 
“relevant” side effects, i.e. those reflecting serious ethical issues (see Table 1). This point 
requires a closer look to the methods and tests used in the outcome studies. We listed all tests 
used in the 347 outcome studies and attributed them to one of the 18 issue groups. Far most of 
the tests were assigned to one of the five issue classes B, C, D, L, and Q (group 3), whereas 
the internal distribution is very uneven. Fig. 3.a demonstrates that more than half of all 
methods applied are tests regarding cognitive issues. Also the number of uses of the tests 
themselves is remarkably uneven. Only very few tests are used regularly. Furthermore, the 
probability that a test is used in a study for neuropsychological outcome assessment does not 
correspond completely to the four standards proposed in the literature (Defer et al. 1999, 
Saint-Cyr et al. 2000, Morrison et al. 2000, Pillon 2002). For example, the Hopkins Verbal 
Learning Test and the Odd Man Out Test, both recommended in all four standards, are 
comparably rarely used. This may indicate a learning effect by the community, as better tests 
than the ones initially recommended are available that measure similar constructs.   
 
For the ethical evaluation it is of particular interest which perspectives are represented in the 
tests, as conflicting evaluations of side effects often result from different perspectives of 
stakeholders. For analyzing this point, we have classified all tests as follows: 
 
I) Test scores that result from the evaluation of the patient’s performance by a trained 
evaluator 
II) Test scores that result from a self-assessment of the patient 
III) Test scores that result from an interrogation etc. from closely related persons of the 
patient (family members, caregivers) 
 
In order to avoid biases due to low quality studies, we have only investigated those studies 
that achieved a quality rating of at least 5 (see footnote 1, 182 studies). We have counted the 
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5 
number of different tests, the number of test executions (i.e. in how many studies the test was 
used) and the number of patients that have been tested by these methods. The cumulative 
numbers for the three classes I, II and III are displayed in Fig. 3.b.  
 
INSERT FIGURE 3 
 
Figure 3:  a: Number of tests per issue class (B: behavioral, C: cognitive, D: depression and other mood 
issues, L: language, Q: quality of life). b: Number of different tests (first bar in each group), of 
accumulated test executions (middle bar) and total number of patients tested (left bar, right 
scale) with methods of either class I (test scores generated by evaluator), II (self-assessment of 
patient) or III (test scores emerge from persons affiliated to the patient). 
 
We see a clear dominance of category I tests, whereas the usage of category III tests is 
basically nonexistent. Thus, the perspective on side effects is very biased in the DBS 
literature. This finding might explain the “satisfaction gap” between the physician’s and the 
patient’s expectation that is discussed in the literature (Agid et al 2006).  
 
 
The Ethics of Adverse Events: Conclusions and Recommendations for Psychiatric DBS 
 
What is the impact of this in-depth analysis of the literature about side effects of STN-DBS 
for the ethical debate about the application of DBS in psychiatry? Compared to many somatic 
diseases, harm-benefit-assessments for psychiatric therapies are complicated by at least three 
problems: First, for most psychiatric disorders no clear correlation with a specific 
neurological dysfunction is proven. Second, many interventions affect various neuronal 
mechanisms, e.g., SSRI have effects not only on the serotonin metabolism, but also on the 
neurogenesis in the hippocampus (Santarelli et al. 2003). Third, the evaluation of both the 
disease and the beneficial and negative therapy effects depend much stronger on subjective 
evaluations than this is valid for the somatic medicine. For example, neither patients nor their 
relatives nor their physicians would doubt that toothache is painful, whereas hypomania is 
evaluated differently by different stakeholders (see e.g. the examples in Krug et al. 2010). 
‘Clear-cut’ cases (predictable side effects that clearly outbalance therapeutic effects) are 
probably rather rare in psychiatric diseases.  
 
This is important, since the introduction of DBS to psychiatry is driven also by the 
expectation that it will improve the understanding of the causes of these diseases and that it 
will be a causal therapy. Already the usage of DBS for the treatment of movement disorders 
was accompanied by the narrative that DBS is more precise than its alternatives, completely 
reversible, and individually scalable. Although this is to a large extent true, the problems of 
measuring and evaluating side effects do not vanish. In the contrary, our analysis revealed that 
the availability of a more precise tool triggered research on the mechanisms behind the effects 
of DBS on cognitive functions, mood, and behavior and thus tends to increase the spectrum of 
potential SE to look at. If DBS will play an important role in psychiatry, we cannot expect 
that the SE spectrum will become smaller compared to that implicated by the alternatives. 
 
However, we have found a well-developed sensibility for side effects in the DBS community. 
Nevertheless, the side effects are not yet measured and evaluated sufficiently. Our analysis 
reveals that the majority of methods used investigate subtle cognitive changes which may be 
statistically significant but whose relevance for the patients is unclear. Only a minority of 
investigations focus on the self-assessment of the patients, and even less on the assessments of 
their caregivers. This methodological bias implies blindness for certain side effects. We 
expect that this problem will be aggravated if DBS is used to treat psychiatric disorders as 
Page 5 of 35
URL: http://mc.manuscriptcentral.com/uabn  Email: editor@bioethics.net





























































For Peer Review Only
6 
depression or addiction, since interpersonal relationships play a crucial role in overcoming 
these disorders. 
 
Finally, the quality of studies that promote the extended use of DBS gives cause for concern, 
although we note that our rating system does not take into account that the requirements for 
quality may differ between studies if they addressed different types of outcomes, such that not 
all quality items are required for a specific study. After all, progress is recognizable and the 
community is somewhat able to discriminate between good and bad studies, yet it has not 
managed to cut down the continuous generation of low quality contributions. 
 
In summary, the ethical evaluation of side effects of STN-DBS must not abstract from the 
measurement and evaluation problems that constitute the definition of what counts as a ‘side 
effect’. The role of ethicists is not only to safeguard against the “bad effects” of therapies. 
They should also point at blind spots in clinical studies and widen the perspective on all sorts 
of effects of new therapies. 
 
 
This research has been supported by the Swiss Academy of Medical Sciences (Käthe-Zingg-
Schwichtenberg-Fonds) and by the Federal Ministry of Education and Research, Germany 
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i
 Each study was assigned with points as follows: Study was prospective: +1; study was case-controlled with at 
least 20 participants in each branch: +2 (+1 if less than 20 participants in either branch); study was randomized: 
+1; test evaluation was blinded: +1; study involved more than one center: +1; the pre-surgery and post-surgery 
assessment of the neuropsychiatric tests were made in the “best” (pre: med-on/ post: med-on, stim-on) condition 
of the patient: +2 (+1 if the assessments were made pre and post); the study involved at least 20 patients: +1; the 
study had a follow-up time of at least 12 month: +1; the study involved tests of at least three issue classes: +1. 
ii
 The citation coefficient was construed as follows: We counted the appearance of outcome studies in the 
analytic part of reviews that either performed a meta-analysis following established standards (e.g. Cochrane) or 
were at least systematically evaluated (i.e. we excluded merely narrative reviews; thus we considered 23 
reviews). The citation of outcome papers is weighted with the probability of being able to be cited due to the 
year of publication to take into account, that a paper e.g. published in 2006 cannot be cited in a review published 
in 2004. Thus each outcome paper received a citation coefficient value between 0 and 1. For the correlation 
analysis, only outcomes with nonzero citation coefficient have been analyzed. 
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The histogram displays the total number of issues (compare with Table 2) addressed in the 
publications about STN-DBS (case reports, reviews, and outcome studies) pooled in four groups 
(Group 1: F, M, V / Group 2: O, P, T / Group 3: B, C, D, L, Q / Group 4: A, E, I, K, N, S, W; see 
text).  
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(a) Quality rating distribution of the outcome studies of group 3, (b) time-course of the mean 
quality rating of outcome studies (group 3), (c) correlation between the citation coefficient of 
studies (which reflects the appreciation of papers by the authors of reviews) with the quality rating 
of the studies. The chart also includes the linear approximation of the correlation.  
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a: Number of tests per issue class (B: behavioral, C: cognitive, D: depression and other mood 
issues, L: language, Q: quality of life). b: Number of different tests (first bar in each group), of 
accumulated test executions (middle bar) and total number of patients tested (left bar, right scale) 
with methods of either class I (test scores generated by evaluator), II (self-assessment of patient) 
or III (test scores emerge from persons affiliated to the patient).  
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Predictability of side effects (SE) of a therapy  
predictable not predictable 
The SE of the therapy 
clearly outweighs its 
therapeutic effects. 
Do not begin / stop the therapy. Ensure sensibility for novel SE. 
There are conflicting 
evaluations of the SE 
by different 
stakeholders. 
Define the authority to decide about 
the usage of the therapy. 
Ensure involvement of different 
stakeholder’s perspectives during the 










outbalance the SE. 
Define a procedure to take individual 
variability of the impact of the SE 
into account. 
Define a procedure to decide whether 
a novel SE is classified as 
unproblematic or not. 
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 Abbr. Issue class Examples of side effects 
F Functional studies, i.e. studies that involve PET 
or other methods for investigating the causal 
effect of DBS 
- 
M Motor effects 
 
Apraxia, axial symptoms, dyskinesia, dystonia, 





V Issues related to Levodopa and other 
medication 
Dopamine dysregulation syndrome, changes in 
LEDD 
O Operation/surgery related issues 
 
Hemorrhage, hematoma, ischemia, surgical 
complications, infections 
P Patient issues, i.e. issues related to patient 







T Effects related to the technology (device) 
 
Battery problems, electrode break, local infections, 
lead fracture, pulse generator malfunction 
B Behavioral effects, i.e. effects that concern 
abnormal behavior  
Compulsive shopping, hypersexuality, hypomania, 
pathological gambling, suicide (attempts) 
C Effects on cognition (reasoning, memory etc.) Cognitive decline, confusion, dementia, memory 
decline, verbal fluency 
D Depression, anxiety, apathy and other mood 
effects 
Ahedonia, apathy, depression, mood changes, 
sadness 
L Language, i.e. effects regarding the general 
speech ability and motor aspects of speech 
Aphasia, dysarthria, hypophonia, speech 






Q Quality of life and social aspects Disability in daily living, decreased life 
satisfaction, partnership problems 
A Effects regarding the autonomous nervous 
system, autonomous functioning 
Drooling, dysphagia, hyperhidrosis 
E Emotion recognition changes Difficulties of emotion discrimination, difficulties 
of face perception, hyperemotivity 
I Insomnia, i.e. effects related to sleep 
 
Drowsiness, fatigue, insomnia, sleep disorders 
K Cost issues (German: Kosten), i.e. cost-benefit-
studies, cost-effectiveness of DBS etc. 
- 
N Other neurological effects 
 
Epilepsy, postural imbalance, seizures 
S Effects regarding sensory systems 
 






W Weight and energy intake changes 
 
Abnormal weight gain, binge eating, obesity 
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